SCHEMBL1665528

SCHEMBL1665528

Clc1ccc2nc(C3CC3)cn2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.56
NPC1 O15118 7/20 0.56
ALDH1A1 P00352 9/20 0.49
KDM4E B2RXH2 8/20 0.49
MAPT P10636 5/20 0.49
SMN1; SMN2 Q16637 5/20 0.49
POLB P06746 3/20 0.49
LMNA P02545 1/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
APP P05067 1/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 3/20 0.42
HRH4 Q9H3N8 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH1A3 P47895 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19444520 0.92 RAB9A (0.49) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL19444521 0.88 RAB9A (0.45) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL5055929 0.78 APP (0.46) RAB9ANPC1APPALDH1A3MCHR1
SCHEMBL1500181 0.78 PIK3CG (0.55) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL22235439 0.78 MCHR1 (0.41) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL17810233 0.78 APP (0.46) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL20619247 0.75 PDE10A (0.44) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL22259100 0.75 MCHR1 (0.48) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL31075248 0.75 MCHR1 (0.38) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL7911725 0.74 RAB9A (0.60) RAB9ANPC1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891042-B1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA SA (BE) 2013-10-02 EP disclosed
US-8178533-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2012-05-15 US disclosed
EP-2308870-A2 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses UCB Pharma S.A. (BE) 2011-04-13 EP disclosed
EP-2308867-A2 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses UCB Pharma S.A. (BE) 2011-04-13 EP disclosed
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312333-A1 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses CYP3A4, CYP1B1, CYP2D6 RAB9A 547/4885NPC1 416/4885ALDH1A1 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.